---
title: "AN2 Therapeutics, Inc. (ANTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ANTX.US.md"
symbol: "ANTX.US"
name: "AN2 Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-01T09:07:29.154Z"
locales:
  - [en](https://longbridge.com/en/quote/ANTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ANTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ANTX.US.md)
---

# AN2 Therapeutics, Inc. (ANTX.US)

## Company Overview

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.an2therapeutics.com](https://www.an2therapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.66 | 151 | - | - | - |
| PB | 3.09 | 110 | 0.54 | 0.49 | 0.45 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-11T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.55 |
| Highest Target | 1.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ANTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ANTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ANTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ANTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**